Chronic Kidney Disease Drugs Market, by Drug Class, by Route of Administration, by Patient Type by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022

Description

Chronic kidney disease is a condition which is characterized by gradual loss of kidney function over time. Chronic kidney disease is also known as chronic renal disease. The kidney disease gets worse, wastes can build to high levels in your blood; other problems associated to chronic kidney disease are high blood pressure, a low red blood cell count, weak bones, poor nutrition, and nerve damage.

The main causes of chronic kidney disease include diabetes, hypertension, chronic glomerulonephritis, chronic pyelonephritis, chronic use of anti-inflammatory medication, autoimmune diseases, polycystic kidney disease, Alport disease, congenital malformations, and prolonged acute renal disease.

Market Dynamics

Key players in market are focused on gaining approvals from regulatory bodies, which is expected to drive the market growth over the forecast period. For instance, in September 2020, Ardelyx, Inc., a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

Factors such as awareness initiatives by government bodies, increasing prevalence of chronic kidney disease, and product launches are driving the global chronic kidney disease drugs market growth. For instance, according to an article published by Centers for Disease Control and Prevention in 2021, more than 1 in 7, that is 15% of the U.S. adults or 37 million people, are estimated to have chronic kidney disease. According to same source, chronic kidney disease is more common in people aged 65 years or older (38%) than in people aged 45-64 years (12%) or 18-44 years.

Key features of the study:

This report provides an in-depth analysis of the global chronic kidney disease drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market.

Detailed Segmentation:

Global Chronic Kidney Disease Drugs Market, By Drug Class:
- ACE Inhibitors
- Angiotensin Receptor Blockers (ARBs)
- B-Blockers
- Calcium Channel Blockers
- Loop Diuretics
- Erythropoiesis-Stimulating Agents (ESAs)
- Phosphate Binders
- Others
Global Chronic Kidney Disease Drugs Market, By Route of Administration:
- Oral
- Subcutaneous
- Intravenous
Global Chronic Kidney Disease Drugs Market, By Patient Type:
- Dialysis
- Others
Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Chronic Kidney Disease Drugs Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region/Country
- South Africa
- Central Africa
- North Africa
Company Profiles
- Sanofi*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AstraZeneca plc.
- Amgen, Inc.
- Regeneron Pharmaceuticals, Inc.
- AbbVie Inc.
- ProKidney Corp.
- Pfizer, Inc.
- Bayer AG
- Hoffmann-La Roche AG
- Kissei Pharmaceutical Co., Ltd.
- Reata Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- Ardelyx, Inc.
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Novartis AG
- Johnson & Johnson
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Kibow Biotech, Inc.
- FibroGen, Inc.
- Cara Therapeutics
- Pieris Pharmaceuticals, Inc.
- Mitsubishi Chemical Group Corporation
- Pharmacosmos A/S
- OPKO Health, Inc.
- Covis Pharma
- Tricida, Inc.
- Eli Lilly and Company
- Biosidus S.A.
- Teva Pharmaceutical Industries Ltd.
- YUHAN
- Caladrius Biosciences, Inc.
- UnicoCell Biomed CO. LTD
- Akebia Therapeutics, Inc.
- Allena Pharmaceuticals
- KBP Biosciences Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI1713

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Patient Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Key Highlights
Research and Development
Collaboration, Mergers, and Acquisitions Scenario
Key Development
Recent Product Approvals and Launches
PEST Analysis
Pipeline Analysis
Epidemiology

4. Global Chronic Kidney Disease Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

COVID-19 Impact on the market
Impact on Global Chronic Kidney Disease Drugs Market
Impact on Clinical Trials

5. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
ACE Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Angiotensin Receptor Blockers (ARBs)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
B-Blockers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Calcium Channel Blockers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Loop Diuretics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Erythropoiesis-Stimulating Agents (ESAs)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Phosphate Binders
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Chronic Kidney Disease Drugs Market, By Route Of Administration, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Subcutaneous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Intravenous
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Chronic Kidney Disease Drugs Market, By Patient Type, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Dialysis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global Chronic Kidney Disease Drugs Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Heat Map Analysis
Company Profiles
- Sanofi
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- AstraZeneca plc.
- Amgen, Inc.
- Regeneron Pharmaceuticals, Inc.
- AbbVie Inc.
- ProKidney Corp.
- Pfizer, Inc.
- Bayer AG
- F. Hoffmann-La Roche AG
- Kissei Pharmaceutical Co., Ltd.
- Reata Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- Ardelyx, Inc.
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Novartis AG
- Johnson & Johnson
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Kibow Biotech, Inc.
- FibroGen, Inc.
- Cara Therapeutics
- Pieris Pharmaceuticals, Inc.
- Mitsubishi Chemical Group Corporation
- Pharmacosmos A/S
- OPKO Health, Inc.
- Covis Pharma
- Tricida, Inc.
- Eli Lilly and Company
- Biosidus S.A.
- Teva Pharmaceutical Industries Ltd.
- YUHAN
- Caladrius Biosciences, Inc.
- UnicoCell Biomed CO. LTD.
- Akebia Therapeutics, Inc.
- Caladrius Biosciences, Inc.
- Allena Pharmaceuticals
- KBP Biosciences Co., Ltd.

11. Section

References
Research Methodology
About Us and Sales Contact

Chronic Kidney Disease Drugs Market, by Drug Class, by Route of Administration, by Patient Type by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030